Company: NCNA
Filing Date: 2025-05-02
Form Type: F-1/A
Source: 0001193125-25-110310
Chunk: 18

Company: NuCana plc
Filing Date: 2025-05-02
Form: F-1/A
Chunk 18
---
 the 
 completion of this offering. See “Description of Share Capital” in this prospectus.                                                                                                                                                         |

| Use of proceeds | We estimate that the net proceeds from this offering will be approximately $5.5 million, at an assumed public offering price of $0.5601 per ADS and accompanying Series A Warrant and Series B Warrant, which was the closing price of our ADSs 
 on The Nasdaq Capital Market on April 28, 2025, after deducting the Placement Agent fees and estimated offering expenses payable by us, assuming no Pre-Funded Warrants are issued.                                                             |

| We intend to use the net proceeds of this offering, together with our existing cash and cash equivalents, to fund activities relating to the advancement of our drug discovery and development programs, and for other    
 general corporate purposes, including, but not limited to, working capital, capital expenditures, investments, acquisitions, should we choose to pursue any, and collaborations See “Use of Proceeds” in this prospectus. |

| Risk factors | You should carefully read the information set forth under “Risk Factors” beginning on page 8 of this prospectus, and incorporated by referenced in this prospectus, before investing in our securities. |

| Reasonable best efforts offering | We have agreed to offer and sell the securities offered hereby to the purchasers through the Placement Agent. The Placement Agent is not required to buy or sell any specific number or dollar amount of the securities offered hereby but will 
 use its reasonable best efforts to solicit offers to purchase the securities offered by this prospectus. See “Plan of Distribution” on page 69 of this prospectus.                                                                              |

| Nasdaq Capital Market symbol | Our ADSs are listed on The Nasdaq Capital Market under the symbol “NCNA”. There is no established trading market for the Pre-Funded Warrants, Series A Warrants or Series B Warrants and we do not           
 expect a trading market to develop. We do not intend to list the on any securities exchange or other trading market. Without a trading market, the liquidity of the Pre-Funded Warrants and Warrants will be 
 extremely limited.                                                                                                                                                                                           |

The number of our ordinary shares to be outstanding immediately after this offering is calculated by reference to our entire issued share capital of 142,037,199 ordinary shares as of December 31, 2024 and excludes as of that date:

| • |     | 17,175,304 ordinary shares issuable upon exercise of outstanding options under our equity compensation plans as 
 of